These findings not only confirm the therapeutic effect of FGF19 on Wolman disease but also demonstrate that HLOs produced by iPSCs show genetic specificity for Wolman patients and may be more widely used for in vitro drug screening of other genetic illnesses in the future. The gene discussed is FGF19; the disease is Wolman disease.